Aytu Biopharma Inc (AYTU) — 13F Holders Deep Dive (Q2 2026)

AYTU ranks #6879 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

38 institutions disclose a position in AYTU, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 4.5% of its own portfolio to it.

Stonepine Capital Management, LLC has added to its AYTU position for two straight quarters, increasing it by $7.5M to reach $9.6M today.

XTX Topco Ltd has trimmed its AYTU position for two straight quarters, cutting it by $21.2K while still holding $46.0K.

AYTU is up 1.3% today, and institutions have been net buyers of $8.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AYTU reported a net loss of $34.1M over the trailing twelve months.

• Not yet profitable — net loss of $34.1M over the trailing twelve months
• Revenue grew 6.0% year over year
• Net income declined year over year, from $1.6M to -$34.1M
• Operating cash flow was negative, using $1.9M in cash
• Current ratio of 1.26x — below the conventional 1.5x liquidity buffer
• Liabilities run 6.55x equity — a highly leveraged balance sheet worth noting